Physician profile
David Seastone
NPI 1629211982
$4,185.09
in general payments reported to CMS, 2019-2025
29 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,220 · 2021: $11.92 · 2022: $282 · 2023: $15.88 · 2024: $2,531 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,498 · Food and Beverage: $157 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,497.50 |
| Food and Beverage | $157.12 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,707.21 | 2019-2024 | Imfinzi, Lynparza, Calquence |
| Merck Sharp & Dohme LLC | $197.90 | 2019 | |
| Pfizer INC. | $157.53 | 2019 | |
| Rigel Pharmaceuticals, INC. | $125.13 | 2022 | |
| Adc Therapeutics America, INC. | $124.74 | 2025 | |
| Janssen Biotech, INC. | $115.96 | 2019 | |
| Tesaro, INC. | $110.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $75.08 | 2019 | |
| Genentech USA, INC. | $58.36 | 2019 | |
| Lilly USA, LLC | $46.30 | 2019 | |
| Amgen INC. | $36.07 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $32.68 | 2019 | |
| Astellas Pharma US INC | $29.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.31 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.99 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $23.68 | 2019 | |
| Eisai INC. | $23.57 | 2019 | |
| Clovis Oncology, INC. | $20.71 | 2019 | |
| Boston Scientific Corporation | $17.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2024 | Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.53 | 2019 | |
| Life Molecular Imaging LTD | $16.50 | 2024 | Neuraceq |
| Verastem, INC. | $16.20 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.79 | 2019 | |
| Seagen INC. | $12.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $12.26 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Seastone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.